文献速递慢阻肺呼吸道感染

噻托溴铵治疗支气管扩张:随机安慰剂对照交叉试验

Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.
PubMed 文献 · Eur Respir J · 2022-06-09

在新西兰三所医院开展的随机双盲两周期交叉试验中,90例稳定期支气管扩张伴气流受限患者接受噻托溴铵18μg每日一次或安慰剂治疗6个月。结果显示噻托溴铵未显著降低年加重率(2.17 vs 2.27次/年,率比0.96,95%CI 0.72-1.27,p=0.77),但FEV1较安慰剂提高58 mL(95%CI 23-92 mL,p=0.002),不良事件相似。

要点

  • 噻托溴铵18μg每日一次治疗6个月未减少支气管扩张患者的加重频率。
  • 噻托溴铵显著改善FEV1,较安慰剂提高58 mL(95%CI 23-92 mL,p=0.002)。
  • 噻托溴铵与安慰剂的不良事件相似。

核心结论

  • 噻托溴铵经HandiHaler装置治疗6个月可显著改善稳定期支气管扩张伴气流受限患者的肺功能,但未降低加重频率。

研究设计与样本

  • 随机、双盲、两周期交叉试验,从新西兰三所医院招募成人患者,排除吸烟史>20包年者。
  • 90例患者随机分配至噻托溴铵-安慰剂或安慰剂-噻托溴铵序列,1:1比例,按中心分层随机区组,85例完成两个治疗周期。
  • 噻托溴铵18μg经HandiHaler每日一次治疗6个月,安慰剂治疗6个月,洗脱期4周。

主要发现

  • 噻托溴铵治疗期间年加重率为2.17次/年,安慰剂为2.27次/年(率比0.96,95%CI 0.72-1.27;p=0.77)。
  • 噻托溴铵较安慰剂提高FEV1 58 mL(95%CI 23-92 mL;p=0.002)。
  • 两种治疗的不良事件相似。

临床怎么用

  • 对于稳定期支气管扩张伴气流受限患者,噻托溴铵可考虑用于改善肺功能,但不应期望减少加重。
  • 治疗决策需结合患者加重频率和肺功能情况个体化评估。

局限性

  • 研究纳入排除吸烟史>20包年者,结果可能不适用于重度吸烟相关支气管扩张患者。
  • 样本量90例随机、85例完成,结论需进一步研究验证临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tiotropium via the HandiHaler device is an established long-acting, anticholinergic bronchodilator that prevents exacerbations and improves lung function in patients with chronic obstructive pulmonary disease. We hypothesised that tiotropium would reduce pulmonary exacerbations and improve lung function in patients with stable bronchiectasis and airflow limitation, and assessed the effect of tiotropium on these outcomes. METHODS: In a randomised, double-blind, two-period crossover trial, we recruited adult patients from three hospitals in New Zealand. Patients were excluded if they had a smoking history of >20 pack-years. Patients were assigned to either the tiotropium-placebo or placebo-tiotropium sequence in a 1:1 ratio, using randomly permuted blocks stratified by centre. Participants and investigators were masked to treatment allocation. Eligible patients received tiotropium 18 μg via HandiHaler daily for 6 months followed by 6 months of placebo, or vice versa, with a washout period of 4 weeks. The primary end-point was rate of event-based exacerbations during the 6-month period. Primary analyses were carried out in an intention-to-treat set. RESULTS: 90 patients were randomly assigned and 85 completed both treatment cycles. The rate of exacerbations was 2.17 per year under the tiotropium treatment and 2.27 per year under placebo (rate ratio 0.96, 95% CI 0.72-1.27; p=0.77). Tiotropium, compared with placebo, improved forced expiratory volume in 1 s by 58 mL (95% CI 23-92 mL; p=0.002). Adverse events were similar under both treatments. CONCLUSIONS: Tiotropium via HandiHaler over 6 months significantly improved lung function but not frequency of exacerbations. Further research is required to understand the clinical context and significance of these findings.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Jayaram L, Vandal AC, Chang CL, et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J. 2022. PMID: 34795034. doi:10.1183/13993003.02184-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。